Biotin, Vitamin D and B12: Where Deficiency Matters, Where It Does Not, and the Lab Notice Practices Miss

Biotin is the component of a hair protocol that patients ask for most often and that the evidence supports least, and it is the one that can quietly corrupt a laboratory result. Vitamin D is the cofactor with the strongest association literature and the weakest intervention literature. Iron, zinc and the B vitamins sit between the two, useful where a deficiency has been documented and unsupported where it has not. A compounded formulary lists injectable biotin, vitamin D3 and methylcobalamin, and a practice that sources them is well served by holding the distinction between an association and an intervention through every line of this article.

This article sets out what the meta-analyses report on vitamin D and the alopecias, what the reviews conclude about biotin and why the FDA issued a laboratory notice about it, what the iron and trace-element literature contains, where thyroid sits as a laboratory question, and what a compounded injectable is under section 503A. It attributes every finding to the study that reported it, makes no claim about what any supplement does to hair, and leaves the ordering of labs and the prescribing decision with the prescriber.

An association is a correlation with a lab value, and an intervention is a trial

The nutritional literature on hair is built almost entirely on the first kind of study and almost never on the second, and the distinction decides what any of it means for a formulary. An analogy that holds for the logic and not for any biology is a weather station that records that rainy days are cloudier: the correlation is real, and no one concludes that clearing the clouds will stop the rain. A meta-analysis reporting that people with an alopecia are more often deficient in a vitamin establishes an association; only a trial in which the vitamin is given and hair is measured establishes whether giving it changes anything, and for most cofactors that trial has not been done.

Almohanna and colleagues reviewed the role of vitamins and minerals in hair loss in Dermatology and Therapy in 2019, and that review is the standard map of the field. It reads, cofactor by cofactor, as a list of associations with a small number of interventions attached, and the sections below follow it.

Vitamin D has the strongest association literature and no intervention trial for pattern loss

Yongpisarn and colleagues published a systematic review and meta-analysis in Frontiers in Nutrition in 2024 across non-scarring and scarring alopecias and reported vitamin D deficiency in roughly 52% of patients with alopecia areata, 50% with female pattern hair loss, 47% with male androgenetic alopecia, 54% with telogen effluvium and 39% with primary scarring alopecia. Chen and colleagues reported a separate 2024 meta-analysis of serum 25-hydroxyvitamin D in non-scarring alopecia in the Journal of Cosmetic Dermatology, and two earlier meta-analyses, by Lee and colleagues in 2018 and Liu and colleagues in 2020, reported a higher prevalence of deficiency in alopecia areata than in controls.

That is a consistent association across four meta-analyses, and it is the reason vitamin D appears on a prescriber’s laboratory panel for a patient with shedding. It is also, in every one of those papers, an association: none of them is a trial of vitamin D given to people with pattern hair loss, and the authors say so. The compounded formulary lists an injectable vitamin D3 preparation; what the literature supports is measuring the level, and what a prescriber does with a low result is a prescribing decision this article does not make.

Biotin is supported in deficiency states and unsupported without them, and it interferes with lab tests

Yelich and colleagues reviewed the biotin literature in the Journal of Clinical and Aesthetic Dermatology in 2024 and concluded that the available human evidence supports biotin only in documented deficiency states and in specific inherited or medication-related conditions, including biotinidase and holocarboxylase deficiency, uncombable hair syndrome, insufficient intake in parenteral nutrition or after bowel surgery, and exposure to isotretinoin or valproic acid. They found no support for routine supplementation in people without deficiency, and they noted a double-blind placebo-controlled study that found no difference between biotin and placebo on hair growth. Patel and colleagues had reached the same conclusion in Skin Appendage Disorders in 2017.

The FDA’s interest in biotin is about laboratory assays rather than about hair. In a safety communication first issued in 2017 and updated on November 5, 2019, the agency warned that biotin in a patient’s blood sample can interfere with immunoassays that use biotin technology, producing falsely high or falsely low results depending on the assay, and it was particularly concerned about falsely low troponin, the biomarker used to diagnose heart attack. A patient taking biotin is therefore a laboratory disclosure item: the laboratory needs to know, and cardiovascular and hormone assays are among those the agency named as potentially affected.

That notice is the reason this series lists injectable biotin under context rather than under evidence. The compounded formulary lists it, the literature supports it only where a deficiency has been documented, and the FDA communication attaches to every patient who takes it regardless of why.

Iron, zinc and the trace elements: measured more often than they are trialled

Treister-Goltzman and colleagues published a systematic review and meta-analysis of iron deficiency and non-scarring alopecia in women in Skin Appendage Disorders in 2022 and reported an association between low iron status and non-scarring hair loss, and Zhang and colleagues published a clinical guide to serum ferritin in patients with hair loss in Cutis in 2023 that sets out how the value is read and where the thresholds in the literature disagree. Ahmed and colleagues published a 2026 systematic review and meta-analysis of serum trace elements and telogen effluvium that reported associations for several elements and the same absence of intervention trials.

Klein and colleagues, in a 2022 retrospective chart review in JAAD International, examined patients with alopecia and laboratory abnormalities who were supplemented, and reported on hair growth in that selected group; a chart review of supplemented patients is the closest the field comes to an intervention study for most cofactors, and it is a chart review. The compounded formulary lists methylcobalamin and a B-complex injectable; the literature on the B vitamins and hair is, again, deficiency literature.

Thyroid is a laboratory question that belongs beside the cofactors

Hussein and colleagues reviewed the impact of thyroid dysfunction on hair disorders in Cureus in 2023 and described diffuse shedding in both hypothyroidism and hyperthyroidism, which is why thyroid function sits on the same laboratory panel as vitamin D, ferritin and zinc when a prescriber evaluates shedding. The hormonal context article later in this series takes thyroid and the sex steroids at their own level of detail; here the point is only that a nutritional panel and a thyroid panel are usually drawn together, and that both are ordered by a prescriber for a reason this page does not supply.

What a compounded injectable is, and what the literature supports for each

Every injectable on that table is prepared under section 503A to an individual prescription and has not been evaluated by the FDA for safety, effectiveness or quality, as the FDA’s questions and answers on compounding state. None is FDA-approved for hair. The compounded formulary lists them by strength, container and beyond-use date, and the vitamins and injectables page on this site does the same.

Closing Observation

The nutritional literature on hair is a literature of associations, and it is honest about that in every meta-analysis it contains. Vitamin D deficiency is common across the alopecias and untested as an intervention in pattern loss; biotin is supported only where a deficiency exists and carries an FDA notice that applies to every laboratory sample; iron and the trace elements are measured far more often than they are trialled. A prescriber orders the panel because the associations are real, and reads the result knowing that a low value and a reason to supplement are two different findings.

What the literature does not support is the conversion of a laboratory association into a formulary claim, which is the step the supplement market performs by default. A practice that keeps the two apart will draw the panel for the right reasons, will tell its laboratory which patients take biotin, and will be considerably harder to sell a vitamin to on the strength of a correlation with a blood test.